Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25116020 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Fabienne R S Adriaanse und 7 weiteren Autor:innen. Beteiligte Einrichtung: Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Myeloid-Lymphoid Leukemia Protein, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Proto-Oncogene Proteins. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) exhibit favorable survival rates. However, for AML and ALL patients carrying KMT2A gene translocations clinical outcome remains unsatisfactory. Key players in KMT2A-fusion-driven leukemogenesis include menin and DOT1L. Recently, menin inhibitors like revumenib have garnered attention for their potential therapeutic efficacy in treating KMT2A-rearranged acute leukemias. However, resistance to menin inhibition poses challenges, and identifying which patients would benefit from revumenib treatment is crucial. Here, we investigated the in vitro response to revumenib in KMT2A-rearranged ALL and AML. While ALL samples show rapid, dose-dependent induction of leukemic cell death, AML responses are much slower and promote myeloid differentiation. Furthermore, we reveal that acquired resistance to revumenib in KMT2A-rearranged ALL cells can occur either through the acquisition of MEN1 mutations or independently of mutations in MEN1. Finally, we demonstrate significant synergy between revumenib and the DOT1L inhibitor pinometostat in KMT2A-rearranged ALL, suggesting that such drug combinations represent a potent therapeutic strategy for these patients. Collectively, our findings underscore the complexity of resistance mechanisms and advocate for precise patient stratification to optimize the use of menin inhibitors in KMT2A-rearranged acute leukemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
- Department of Pediatric Oncology, Erasmus MC-Sophia's Children's Hospital, 3015 CN Rotterdam, The Netherlands.
ORCID-Profile: Fabienne R S Adriaanse, Pauline Schneider, Janine Stutterheim
Zitieren
APA
Adriaanse, F. R. S., Schneider, P., Arentsen-Peters, S. T. C. J. M., Fonseca, A. M. N. D., Stutterheim, J., Pieters, R., Zwaan, C. M., & Stam, R. W. (2024). Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116020
Vancouver
Adriaanse FRS, Schneider P, Arentsen-Peters STCJM, Fonseca AMND, Stutterheim J, Pieters R, et al. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116020
BibTeX
@article{Adriaanse2024,
author = {Adriaanse, Fabienne R S and Schneider, Pauline and Arentsen-Peters, Susan T C J M and Fonseca, Ana M Neves da and Stutterheim, Janine and Pieters, Rob and Zwaan, C Michel and Stam, Ronald W},
title = {Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25116020}
}
EUVIMED